STAT October 11, 2024
Allison DeAngelis, Adam Feuerstein

The former CEO of Alnylam spoke with STAT about RNAi molecules and more

It’s been two years since Alnylam’s founding CEO John Maraganore announced he was stepping back from the company. And in that time, he’s built up a bit of a persona for himself as biotech’s elder statesman. Multiple venture capital firms have enlisted his help in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article